​

Seres Therapeutics (MCRB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MCRB Stock Forecast

Seres Therapeutics (MCRB) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $1.25, with a high of $1.25 and a low of $1.25. This represents a 54.32% increase from the last price of $0.81.

High: $1.25 Avg: $1.25 Low: $1.25 Last Closed Price: $0.81

MCRB Stock Rating

Seres Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

MCRB Forecast vs Benchmarks

TypeNameUpside
StockSeres Therapeutics54.32%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$1.25
Last Closing Price$0.81$0.81$0.81
Upside/Downside--54.32%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25-41-27
Dec, 24-41-27
Nov, 24342-211
Oct, 243431213
Sep, 243431112
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 07, 2024Keay NakaeChardan Capital$1.25$0.8547.06%54.32%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Sep 12, 2024Cowen & Co.BuyBuyhold
Jun 07, 2024OppenheimerOutperformPerformdowngrade
May 09, 2024OppenheimerOutperformOutperformhold
Mar 06, 2024Chardan CapitalBuyBuyhold
Apr 28, 2023Chardan CapitalBuyBuyhold
Sep 07, 2022Piper SandlerOverweightOverweighthold
Jun 08, 2022JefferiesBuyupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.08$-0.67$-2.35$-0.89-----
Avg Forecast$-1.10$-0.62$-2.16$-0.99$-0.12$-0.33$-0.37$-0.29$-0.70
High Forecast$-1.10$-0.62$-2.16$-1.08$-0.30$-0.43$-0.76$-0.62$-0.70
Low Forecast$-1.10$-0.62$-2.16$-0.91$-0.03$-0.15$0.05$0.05$-0.70
Surprise %-1.82%8.06%8.80%-10.10%-----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$33.22M$144.93M$7.13M$126.33M-----
Avg Forecast$22.59M$149.82M$13.76M$126.07M$31.00M$33.08M$25.00M$125.00M$296.16M
High Forecast$22.59M$149.82M$13.76M$125.93M$31.00M$33.08M$25.00M$125.00M$296.16M
Low Forecast$22.59M$149.82M$13.76M$126.43M$31.00M$33.08M$25.00M$125.00M$296.16M
Surprise %47.01%-3.27%-48.18%0.20%-----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-86.45M$-61.50M$-253.82M$-113.72M-----
Avg Forecast$-141.12M$-78.79M$-276.97M$-126.94M$-20.81M$-37.00M$-45.12M$-55.04M$-90.22M
High Forecast$-141.12M$-78.79M$-276.97M$-137.89M$-37.98M$-55.12M$-97.19M$-79.61M$-90.22M
Low Forecast$-141.12M$-78.79M$-276.97M$-115.98M$-3.64M$-18.88M$6.94M$6.42M$-90.22M
Surprise %-38.74%-21.95%-8.36%-10.41%-----

MCRB Forecast FAQ

Is Seres Therapeutics stock a buy?

Seres Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Seres Therapeutics is a favorable investment for most analysts.

What is Seres Therapeutics's price target?

Seres Therapeutics's price target, set by 4 Wall Street analysts, averages $1.25 over the next 12 months. The price target range spans from $1.25 at the low end to $1.25 at the high end, suggesting a potential 54.32% change from the previous close price of $0.81.

How does Seres Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Seres Therapeutics stock forecast shows a 54.32% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Seres Therapeutics over the past three months?

  • January 2025: 0% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 28.57% Strong Sell.
  • December 2024: 0% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 28.57% Strong Sell.
  • November 2024: 27.27% Strong Buy, 36.36% Buy, 18.18% Hold, 0% Sell, 18.18% Strong Sell.

What is Seres Therapeutics’s EPS forecast?

Seres Therapeutics's average annual EPS forecast for its fiscal year ending in December is -0.12 for 2024, a -86.52% decrease from the reported $-0.89 in 2023. The prediction for 2025 is $-0.33, $-0.37 for 2026, $-0.29 for 2027, and $-0.7 for 2028.

What is Seres Therapeutics’s revenue forecast?

Seres Therapeutics's average annual revenue forecast for its fiscal year ending in December is $31M for 2024, a -75.46% decrease from the reported $126.32M in 2023. The forecast for 2025 is $33.08M, $25M for 2026, $125M for 2027, and $296.16M for 2028.

What is Seres Therapeutics’s net income forecast?

For its fiscal year ending in December, Seres Therapeutics's average annual net income forecast is $-20.809M for 2024, reflecting a -81.70% decrease from the reported $-114M in 2023. The projection for 2025 is $-36.997M, $-45.124M for 2026, $-55.039M for 2027, and $-90.217M for 2028.